cannabidiol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Increases serious adverse event incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“This analysis demonstrated an increased risk of serious AEs with the use of CBD when compared to placebo [RD=0.16 (95%CI 0.07–0.26; I2=72%)], NNT=6.”
Quoted verbatim from Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.. - Study
- meta-analysis
- Dose
- 5 to 50 mg/kg/day in two divided doses
- Population
- Children and adults with Dravet syndrome, Lennox-Gastaut syndrome or tuberous sclerosis complex; CBD plus usual antiseizure therapy versus placebo plus usual therapy
Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.2022PMID:36417631Permalink
Keep reading
- Everything the graph holds on cannabidiol
- Every compound studied against Serious adverse event incidence
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45HMS7B6Q9FHH5B5BY82CCC